BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

569 related articles for article (PubMed ID: 35122035)

  • 21. Circulating tumor DNA (ctDNA) is not a good proxy for liquid biopsies of tumor tissues for early detection.
    Fiala C; Diamandis EP
    Clin Chem Lab Med; 2020 Sep; 58(10):1651-1653. PubMed ID: 32160156
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Implementing circulating tumor DNA analysis in a clinical laboratory: A user manual.
    Koessler T; Addeo A; Nouspikel T
    Adv Clin Chem; 2019; 89():131-188. PubMed ID: 30797468
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Circulating cell-free tumor DNA analysis in pediatric cancers.
    Andersson D; Fagman H; Dalin MG; Ståhlberg A
    Mol Aspects Med; 2020 Apr; 72():100819. PubMed ID: 31563277
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Liquid profiling of circulating tumor DNA in colorectal cancer: steps needed to achieve its full clinical value as standard care.
    Hedtke M; Pessoa Rejas R; Froelich MF; Ast V; Duda A; Mirbach L; Costina V; Martens UM; Hofheinz RD; Neumaier M; Haselmann V
    Mol Oncol; 2022 May; 16(10):2042-2056. PubMed ID: 34873826
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Circulating Tumor DNA (ctDNA) Detection Using BEAMing and Its Clinical Significance.].
    Nakamura K
    Rinsho Byori; 2016 May; 64(4):400-406. PubMed ID: 29182806
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ctDNA as a cancer biomarker: A broad overview.
    Pessoa LS; Heringer M; Ferrer VP
    Crit Rev Oncol Hematol; 2020 Nov; 155():103109. PubMed ID: 33049662
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Liquid biopsy: Circulating exosomal long noncoding RNAs in cancer.
    Jiang N; Pan J; Fang S; Zhou C; Han Y; Chen J; Meng X; Jin X; Gong Z
    Clin Chim Acta; 2019 Aug; 495():331-337. PubMed ID: 31054913
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monitoring of cancer patients via next-generation sequencing of patient-derived circulating tumor cells and tumor DNA.
    Onidani K; Shoji H; Kakizaki T; Yoshimoto S; Okaya S; Miura N; Sekikawa S; Furuta K; Lim CT; Shibahara T; Boku N; Kato K; Honda K
    Cancer Sci; 2019 Aug; 110(8):2590-2599. PubMed ID: 31169336
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Commercial ctDNA Assays for Minimal Residual Disease Detection of Solid Tumors.
    Chen K; Shields MD; Chauhan PS; Ramirez RJ; Harris PK; Reimers MA; Zevallos JP; Davis AA; Pellini B; Chaudhuri AA
    Mol Diagn Ther; 2021 Nov; 25(6):757-774. PubMed ID: 34725800
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Introduction and Clinical Application of Cell-Free Tumor DNA.
    Li J; Liu R; Huang C; Chen S; Xu M
    Methods Mol Biol; 2018; 1754():45-65. PubMed ID: 29536437
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Liquid Biopsy Using Cell-Free or Circulating Tumor DNA in the Management of Hepatocellular Carcinoma.
    Lyu X; Tsui YM; Ho DW; Ng IO
    Cell Mol Gastroenterol Hepatol; 2022; 13(6):1611-1624. PubMed ID: 35183803
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time?
    Asante DB; Calapre L; Ziman M; Meniawy TM; Gray ES
    Cancer Lett; 2020 Jan; 468():59-71. PubMed ID: 31610267
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enrichment and Analysis of ctDNA.
    Gilson P
    Recent Results Cancer Res; 2020; 215():181-211. PubMed ID: 31605230
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Liquid Biopsies Using Circulating Tumor DNA in Non-Small Cell Lung Cancer.
    Pellini B; Szymanski J; Chin RI; Jones PA; Chaudhuri AA
    Thorac Surg Clin; 2020 May; 30(2):165-177. PubMed ID: 32327175
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Single tube liquid biopsy for advanced non-small cell lung cancer.
    de Wit S; Rossi E; Weber S; Tamminga M; Manicone M; Swennenhuis JF; Groothuis-Oudshoorn CGM; Vidotto R; Facchinetti A; Zeune LL; Schuuring E; Zamarchi R; Hiltermann TJN; Speicher MR; Heitzer E; Terstappen LWMM; Groen HJM
    Int J Cancer; 2019 Jun; 144(12):3127-3137. PubMed ID: 30536653
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Circulating Tumor DNA in the Management of Early-Stage Breast Cancer.
    Vlataki K; Antonouli S; Kalyvioti C; Lampri E; Kamina S; Mauri D; Harissis HV; Magklara A
    Cells; 2023 Jun; 12(12):. PubMed ID: 37371043
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of Circulating Tumor DNA in Colorectal Cancer.
    Li H; Lu S; Zhou Z; Zhu X; Shao Y
    Methods Mol Biol; 2023; 2695():227-236. PubMed ID: 37450122
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nanotechnology Strategies for the Analysis of Circulating Tumor DNA: A Review.
    Chen X; Wang L; Lou J
    Med Sci Monit; 2020 Mar; 26():e921040. PubMed ID: 32200389
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Liquid biopsy in breast cancer: A comprehensive review.
    Alimirzaie S; Bagherzadeh M; Akbari MR
    Clin Genet; 2019 Jun; 95(6):643-660. PubMed ID: 30671931
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficient detection and monitoring of pediatric brain malignancies with liquid biopsy based on patient-specific somatic mutation screening.
    Kojic M; Maybury MK; Waddell N; Koufariotis LT; Addala V; Millar A; Wood S; Pearson JV; Hansford JR; Hassall T; Wainwright BJ
    Neuro Oncol; 2023 Aug; 25(8):1507-1517. PubMed ID: 36757207
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.